COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,629 Articles (22,913 medRxiv, 8,716 bioRxiv)

Most recent first Previous |  Page 1943: Articles 19421-19430  | Next

Altered kidney function and acute kidney damage markers predict survival outcomes of COVID-19 patients: A prospective pilot study.
Temiz, M. Z., Hacibey, I., Yazar, R. O., Sevdi, M. S., Kucuk, S. H., Alkurt, G., Doganay, L., Dinler-Doganay, G., Dincer, M. M., Yuruk, E., Erkalp, K., Muslumanoglu, A. Y.
10.1101/2021.01.10.20249079 — Posted: 2021-01-12
Convergence of Comorbidity and COVID-19 Infection to Fatality: An Investigation Based on Concurrent Health Status Evaluation among the Elderly Population in Kerala
Joseph, S., Ulahannan, J. P.
10.1101/2021.01.06.20249030 — Posted: 2021-01-12
The hyperlipidaemic drug fenofibrate significantly reduces infection by SARS-CoV-2 in cell culture models
Davies, S. P., Mycroft-West, C. J., Pagani, I., Hill, H. J., Chen, Y.-H., Karlsson, R. T., Bagdonaite, I., Guimond, S. E., Stamataki, Z., Lima, M. A., Turnbull, J. E., Yang, Z., Vicenzi, E. E., Skidmore, M. A., Khanim, F., Richardson, A.
10.1101/2021.01.10.426114 — Posted: 2021-01-11
Microsecond simulation unravel the structural dynamics of SARS-CoV-2 Spike-C-terminal cytoplasmic tail (residues 1242-1273)
Kumar, P., Bhardwaj, T., Giri, R., Garg, N.
10.1101/2021.01.11.426227 — Posted: 2021-01-11
Impact of South African 501.V2 Variant on SARS-CoV-2 Spike Infectivity and Neutralization: A Structure-based Computational Assessment
Cheng, M. H., Krieger, J. M., Kaynak, B., Arditi, M. A., Bahar, I.
10.1101/2021.01.10.426143 — Posted: 2021-01-11
Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques
van Doremalen, N., Purushotham, J., Schulz, J., Holbrook, M., Bushmaker, T., Carmody, A., Port, J., Yinda, K. C., Okumura, A., Saturday, G., Amanat, F., Krammer, F., Hanley, P., Smith, B., Lovaglio, J., Anzick, S., Barbian, K., Martens, C., Gilbert, S. C., Lambe, T., Munster, V.
10.1101/2021.01.09.426058 — Posted: 2021-01-11
COVID-19 Severity Is Associated with Differential Antibody Fc-mediated Innate Immune Functions
Adeniji, O. S., Giron, L. B., Zilberstein, N. F., Shaikh, M. W., Balk, R. A., Moy, J. N., Forsyth, C. B., Keshavarzian, A., Landay, A. L., Abdel-Mohsen, M.
10.1101/2021.01.11.426209 — Posted: 2021-01-11
Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination
Tscherne, A., Schwarz, J. H., Rohde, C., Kupke, A., Kalodimou, G., Limpinsel, L., Okba, N. M. A., Bosnjak, B., Sandrock, I., Halwe, S., Sauerhering, L., Printz, K., Nan, L., Duell, E., Jany, S., Freudenstein, A., Schmidt, J., Werner, A., Gellhorn, M., Kluever, M., Guggemos, W., Seilmaier, M., Wendtner, C., Foerster, R., Haagmans, B., Becker, S., Sutter, G., Volz, A.
10.1101/2021.01.09.426032 — Posted: 2021-01-11
Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class
Rapp, M., Guo, Y., Reddem, E. R., Liu, L., Wang, P., Yu, J., Cerutti, G., Bimela, J., Bahna, F., Mannepalli, S., Zhang, B., Kwong, P. D., Ho, D. D., Shapiro, L., Sheng, Z.
10.1101/2021.01.11.426218 — Posted: 2021-01-11
Immunogenicity and Protective Efficacy of an Intranasal Live-attenuated Vaccine Against SARS-CoV-2 in Preclinical Animal Models
Park, J.-G., Oladunni, F. S., Rohaim, M. A., Whittingham-Dowd, J., Tollitt, J., Assas, B. M., Alhazmi, W., Almilaibary, A., Iqbal, M., Chang, P., Escalona, R., Shivanna, V., Torrelles, J. B., Worthington, J. J., Jackson-Jones, L. H., Martinez-Sobrido, L., Munir, M.
10.1101/2021.01.08.425974 — Posted: 2021-01-11

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).